Roche's Vemurafenib Filed With Companion Diagnostic In Tow
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Roche/Genentech is seeking a broad label in metastatic melanoma for the just-filed oral BRAF inhibitor vemurafenib (formerly PLX4032) and priority review, which could possibly enable a U.S. launch at the end of 2011.